Please assess the completion status of the following clinical trial:

Trial Title: Study of a New Anti-HIV Drug, T-20, in HIV-Infected Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~Children may be eligible for this study if they:~* Are 3 to 12 years old (consent of parent or guardian required).~* Are HIV-positive.~* Are receiving combination anti-HIV therapy. He/she must have been taking this combination for at least 16 weeks, and it must include either 2 NRTIs alone or 2 NRTIs plus either an NNRTI or a PI. (This study has been changed. This no longer has to be a child's first anti-HIV drug combination.)~* Have a viral load greater than 10,000 copies/ml while taking this anti-HIV drug combination.~* Have never received treatment with a PI or an NNRTI. (One or two doses are allowed.)~* Have never taken at least 1 NRTI.~Exclusion Criteria~Children will not be eligible for this study if they:~* Are receiving treatment for an opportunistic (AIDS-related) or serious bacterial infection at the time of study entry.~* Are receiving chemotherapy for cancer.~* Have certain serious diseases (other than HIV) or conditions.~* Have received or are currently receiving certain medications.~* Are pregnant.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).